Lipid profiles of patients as markers for the severity of liver cirrhosis
DOI:
https://doi.org/10.18203/2349-3933.ijam20261086Keywords:
MELD, LDL, HDL, TG, Liver diseaseAbstract
Background: The lipoproteins, endogenous lipids and apolipoproteins are formed in the liver and lipid metabolism, stages of lipid synthesis and transportation are also control by the liver. Degenerated serum lipoprotein pattern can be observed during the acute metabolic impairment in cirrhosis hence, it is reasonable to expect an abnormal lipid profile in those with severe liver dysfunction.
Methods: This cross-sectional study was carried out at a tertiary care hospital, in central Rajasthan among 360 cases of cirrhosis of liver from all causes admitted in Medicine and Gastroenterology wards of Jawaharlal Nehru Medical College, Ajmer. Venous blood sample was collected after overnight fasting of 12 h in all the patients diagnosed with cirrhosis for estimation of hemoglobin, total white blood cell (WBC) count, total platelet count, erythrocyte sedimentation rate (ESR), random blood sugar, blood urea, serum creatinine, liver function tests and serum lipid profile.
Results: The mean high-density lipoprotein (HDL) levels were decreasing statistically with increasing model for end stage liver disease (MELD) score while low-density lipoprotein (LDL) and triglyceride (TG) showed no significant association with increasing MELD score. The sensitivity of HDL in detecting the liver cirrhosis at cut off of 19.3 MELD score was estimated to be 93% and specificity of 82.1%.
Conclusions: The mean HDL levels were significantly decreasing with increasing MELD score and the study of lipid profile of patients may be an alternate to assess the severity of liver cirrhosis.
References
Scaglione S, Kliethermes S, Cao G, Shoham D, Durazo R, Luke A, et al. The epidemiology of cirrhosis in the United States: a population-based study. J Clin Gastroenterol. 2015;49:690-6.
Pimpin L, Cortez-Pinto H, Negro F, Corbould E, Lazarus JV, Webber L, et al. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018;69:718-35.
Singh M, Khan MI, Alam A, Gupta AC, Giri R, Alam A. Role of lipid profile in assessment of severity of cirrhosis. Int J Adv Med. 2019;6:1303-7.
Bassendine MF, Sheridan DA, Bridge SH, Felmlee DJ, Neely RD. Lipids and HCV. Semin Immunopathol. 2013;35(1):87-100.
Cicognani C, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C, Barbara L. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med. 1997;157:792-6.
Etogo-Asse FE, Vincent RP, Hughes SA, Auzinger G, Le Roux CW, Wendon J, et al. High density lipoprotein in patients with liver failure; relation to sepsis, adrenal function and outcome of illness. Liver Int. 2012;32:128-36.
Habib A, Mihas AA, Abou-Assi SG, Williams LM, Gavis E, Pandak WM, et al. High-density lipoprotein cholesterol as an indicator of liver function and prognosis in noncholestatic cirrhotics. Clin Gastroenterol Hepatol. 2005;3:286-91.
Bassani L, Fernandes SA, Raimundo FV, Harter DL, Gonzalez MC, Marroni CA. Lipid Profile of Cirrhotic Patients And Its Association With Prognostic Scores: a cross-sectional study. Arq Gastroenterol. 2015;52(3):210-5.
Haberman PW, Weinbaum DF. Liver cirrhosis with and without mention of alcohol as cause of death. Br J Addict. 1990;85:217-22.
Mokdad AH, Forouzanfar MH, Daoud F, Mokdad AA, El Bcheraoui C, Moradi-Lakeh M, et al. Global burden of diseases, injuries, and risk factors for young people’s health during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2016;387:2383-401.
Beste LA, Leipertz SL, Green PK, Dominitz JA, Ross D, Ioannou GN. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013. Gastroenterology. 2015;149:1471-82.
Pinzani M, Rosselli M, Zuckermann M. Liver cirrhosis. Best Pract Res Clin Gastroenterol. 2011;25(2):281-90.
Crawford JM. Liver cirrhosis. In: MacSween RNM, Burt AD, Portmann BC, editors. Pathology of the Liver. 4th ed. London, England: Churchill Livingstone; 2002:575-619.
Brunt EM. Non-alcoholic fatty liver disease. In: Burt AD, Portmann BC, Ferrell LD, editors. MacSween’s Pathology of the Liver. 5th ed. Philadelphia, PA: Churchill Livingstone. 2007;367-97.
Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151-71.
Freeman RB Jr, Wiesner RH, Harper A, McDiarmid SV, Lake J, Edwards E, et al. UNOS/OPTN Liver Disease Severity Score, UNOS/OPTN Liver and Intestine, and UNOS/OPTN Pediatric Transplantation Committees. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl. 2002;8(9):851-8.
Santoyo J, Suarez MA, FernandezAguilar JL. True impact of the indication of cirrhosis and the MELD on the results of liver transplantation. Transplant Proc. 2006;38(8):2462-4.
Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;17;383(9930):1749-61.
Chiang JY. Nuclear receptor regulation of lipid meta-bolism: potential therapeutics for dyslipidemia, diabetes, and chronic heart and liver diseases. Curr Opin Investing Drugs. 2005;6:9941001.
Jarikre AE, Momoh JAF. Plasma total cholesterol, high density lipoprotein cholesterol and low density lipoprotein cholesterol levels in liver cirrhosis in Nigerians. NigQt J Hosp Med. 1996;6:157-9.
Varghese JS, Krishnaprasad K, Upadhuyay R, Revathy MS, Jayanthi V. Lipoprotein profile in cirrhosis of liver. Eur J Gastroenterol Hepatol. 2007;19(6):521-2.
Phukan JP, Sinha A and Deka JP. Serum lipid profile in alcoholic cirrhosis: A study in a teaching hospital of north-eastern India. Niger Med J. 2013;54(1):5-9.
Mehboob F, Ranjha FA, Masud S. Changes in Serum Lipid Profile Among Patients Suffering From Chronic Liver Disease. Annals of King Edward Medical University. 2007;13(3):209.
Cicognani C, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C and Barbara L. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med. 1997;157(7):792-6.
Suman C, Kumar RB, Prabhakar B. Lipid profile in assessing the severity of cirrhosis. Intl Arch Integrated Med. 2016;3(6):113-23.
Singh M, Khan M, Gupta A, Giri R, Alam, A. Role of lipid profile in assessment of severity of cirrhosis. Int J Adv Med. 2019;6:4.
Chrostek L, Supronowicz L, Panasiuk A, Cylwik B, Gruszewska E, Flisiak R. The effect of the severity of liver cirrhosis on the level of lipids and lipoproteins. Clin Exp Med. 2014;14:417-21.
Habib A, Mihas AA, Abou-Assi SG, Williams LM, Gavis E, Pandak WM, et al. High-density lipoprotein cholesterol as an indicator of liver function and prognosis in noncholestatic cirrhotics. Clin Gastroenterol Hepatol. 2005;3(3):286-91.
Subhan F, Khan I, Arif R, Khan A, Khan A. Serum lipid profile as an indicator of the severity of liver damage in cirrhotic patients. Rawal Med J. 2012;37(4):387-9.
Ghadir MR, Riahin AA, Havaspour A, Nooranipour M, Habibinejad AA. The relationship between lipid profile and severity of liver damage in cirrhotic patients. Hepat Mon. 2010;10:285-8.
Jiang M, Liu F, Xiong WJ, Zhong L, Xu W, Xu F, Liu YB. Combined MELD and blood lipid level in evaluating the prognosis of decompensated cirrhosis. World J Gastroenterol. 2010;16(11):1397-401.
Downloads
Published
How to Cite
Issue
Section
